Nicolas Koebel is the founder of EpilepsyGTx. EpilepsyGTx has raised $43M in total funding. Latest round: Series A. Based in London, United Kingdom.
Nicolas Koebel is the Chief Executive Officer of EpilepsyGTx, a London-based biotechnology company focusing on gene therapies for focal refractory epilepsy. He has led the company since its inception in 2021 as a UCL spinout and oversaw the licensing of three gene therapies from UCL in 2022. Under his leadership, EpilepsyGTx has secured significant funding rounds to advance its lead candidate EPY201 into clinical trials.
Full founder directory · Investor directory · Company funding database · Fundraising library